Trial Profile
A Phase IIIb Open-Label, Single-Arm, Multi-Center, US Study of Bacillus Calmette-Guerin (BCG) Administered in Combination With Durvalumab in Adult BCG-naïve, High-risk Non-Muscle- Invasive Bladder Cancer Participants (PATAPSCO)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs BCG (Primary) ; Durvalumab (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Adverse reactions; Registrational
- Acronyms PATAPSCO
- Sponsors AstraZeneca
- 03 Nov 2023 Planned End Date changed from 31 Dec 2027 to 30 May 2027.
- 03 Nov 2023 Planned primary completion date changed from 31 Aug 2025 to 30 Sep 2025.
- 23 Aug 2023 Planned primary completion date changed from 20 Jul 2027 to 31 Aug 2025.